Cache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Cache Advisors LLC purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 10,143 shares of the company’s stock, valued at approximately $392,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in Protagonist Therapeutics during the 4th quarter worth approximately $48,000. Woodline Partners LP raised its holdings in Protagonist Therapeutics by 24.8% during the 4th quarter. Woodline Partners LP now owns 582,327 shares of the company’s stock worth $22,478,000 after purchasing an additional 115,809 shares during the last quarter. Soleus Capital Management L.P. bought a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at $10,615,000. State of Wyoming increased its stake in shares of Protagonist Therapeutics by 11.9% in the 4th quarter. State of Wyoming now owns 7,832 shares of the company’s stock valued at $302,000 after acquiring an additional 832 shares in the last quarter. Finally, Toronto Dominion Bank bought a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at $13,162,000. Institutional investors own 98.63% of the company’s stock.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 24,903 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total value of $1,462,553.19. Following the transaction, the chief financial officer now owns 62,821 shares in the company, valued at approximately $3,689,477.33. The trade was a 28.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now owns 83,892 shares in the company, valued at $4,676,140.08. This represents a 26.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 61,173 shares of company stock valued at $3,461,180. Insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Trading Down 0.5%

Protagonist Therapeutics stock opened at $45.66 on Friday. The firm’s 50 day simple moving average is $45.86 and its 200 day simple moving average is $42.60. The firm has a market capitalization of $2.83 billion, a PE ratio of 17.17 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 1-year low of $27.00 and a 1-year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Wall Street Analyst Weigh In

PTGX has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Truist Financial boosted their price target on shares of Protagonist Therapeutics from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Tuesday, March 11th. JMP Securities reaffirmed a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, February 7th. BMO Capital Markets boosted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Finally, BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research note on Monday, March 3rd. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $65.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.